Lifeboat Foundation

Both genetically altered and naturally long-lived mammals are more resistant to toxic compounds that may cause cancer and age-associated diseases than their shorter-lived counterparts. The mechanisms by which this stress resistance occurs remain elusive. We found that longer-lived rodent species had markedly higher levels of signaling activity of the multifunctional regulator nuclear factor erythroid 2-related factor (Nrf2) and that this increase in cytoprotective signaling appeared to be due to species differences in Kelch-like ECH-Associated Protein 1 (Keap1) and β-transducin repeat-containing protein (βTrCP) regulation of Nrf2 activity. Both of these negative regulators of Nrf2-signaling activity are significantly lower in longer-lived species. By targeting the proteins that regulate Nrf2 rather than Nrf2 itself, we may be able to identify new therapies that impact aging and age-associated diseases such as cancer.

The preternaturally long-lived naked mole-rat, like other long-lived species and experimental models of extended longevity, is resistant to both endogenous (e.g., reactive oxygen species) and environmental stressors and also resists age-related diseases such as cancer, cardiovascular disease, and neurodegeneration. The mechanisms behind the universal resilience of longer-lived organisms to stress, however, remain elusive. We hypothesize that this resilience is linked to the activity of a highly conserved transcription factor, nuclear factor erythroid 2-related factor (Nrf2). Nrf2 regulates the transcription of several hundred cytoprotective molecules, including antioxidants, detoxicants, and molecular chaperones (heat shock proteins). Nrf2 itself is tightly regulated by mechanisms that either promote its activity or increase its degradation.

Genetic studies of mental illness have largely been conducted in people with European ancestry.

The drug, known as DSP-1181, was created by using algorithms to sift through potential compounds, checking them against a huge database of parameters, including a patient’s genetic factors. Speaking to the BBC, Exscientia chief executive Professor Andrew Hopkins described the trials as a “key milestone in drug discovery” and noted that there are “billions” of decisions needed to find the right molecules for a drug, making their eventual creation a “huge decision.” With AI, however, “the beauty of the algorithm is that they are agnostic, so can be applied to any disease.”

We’ve already seen multiple examples of AI being used to diagnose illness and analyze patient data, so using it to engineer drug treatment is an obvious progression of its place in medicine. But the AI-created drugs do pose some pertinent questions. Will patients be comfortable taking medication designed by a machine? How will these drugs differ from those developed by humans alone? Who will make the rules for the use of AI in drug research? Hopkins and his team hope that these and myriad other questions will be explored in the trials, which will begin in March.

Circa 2013

Tigers and their close relatives (Panthera) are some of the world’s most endangered species. Here we report the de novo assembly of an Amur tiger whole-genome sequence as well as the genomic sequences of a white Bengal tiger, African lion, white African lion and snow leopard. Through comparative genetic analyses of these genomes, we find genetic signatures that may reflect molecular adaptations consistent with the big cats’ hypercarnivorous diet and muscle strength. We report a snow leopard-specific genetic determinant in EGLN1 (Met39Lys39), which is likely to be associated with adaptation to high altitude. We also detect a TYR 260GA mutation likely responsible for the white lion coat colour. Tiger and cat genomes show similar repeat composition and an appreciably conserved synteny. Genomic data from the five big cats provide an invaluable resource for resolving easily identifiable phenotypes evident in very close, but distinct, species.

“It regenerates almost anything after almost any injury that doesn’t kill it,” said Parker Flowers, postdoctoral associate in the lab of Craig Crews, the John C. Malone Professor of Molecular, Cellular, and Developmental Biology and professor of chemistry and pharmacology.

If scientists can find the genetic basis for the axolotl’s ability to regenerate, they might be able to find ways to restore damaged tissue in humans. But they have been thwarted in the attempt by another peculiarity of the axolotl — it has the largest genome of any animal yet sequenced, 10 times larger than that of humans.

Now Flowers and colleagues have found an ingenious way to circumvent the animal’s complex genome to identify at least two genes involved in regeneration, they report Jan. 28 in the journal eLife.

But genetic data tells a very different story.

Due to the groundbreaking work in superlongevity by Dr David Sinclair and Yuancheng Ryan Lu on the Information Theory of Aging and how epigenetic therapy can be used to reverse aging, I suddenly have a compelling interest in epigenetics. Here is a recent research article that I’d recommend on.

Epigenetics can be defined as ‘the structural adaptation of chromosomal regions so as to register, signal, or perpetuate altered activity states.’ Increased transcription of key regulatory, metabolic, and myogenic genes is an early response to exercise and is important in mediating subsequent adaptations in skeletal muscle. DNA hypomethylation and histone hyperacetylation are emerging as important crucial events for increased transcription. The complex interactions between multiple epigenetic modifications and their regulation by metabolic changes and signaling events during exercise, with implications for enhanced understanding of the acute and chronic adaptations to exercise, are questions for further investigation.

Evolutionary Medicine — Linking human pathology with our past, present, and future evolutionary trajectories — ideaXme (http://radioideaxme.com/) welcomes Prof. Dr. Frank Rühli, Director of the Institute of Evolutionary Medicine, University of Zurich — #Ideaxme #EvolutionaryMedicine #Evolution #Microevolution #Paleopathology #BiologicalAnthropology #ComparativeAnatomy #Mummies #Mummy #Hypercholesterinemia #Diabetes #DrugAddiction #Health #Wellness #Regeneration #Longevity #Aging #IraPastor #Bioquark #Regenerage

Ira Pastor, ideaXme exponential health ambassador, interviews Professor Dr. Frank Rühli, Director of the Institute of Evolutionary Medicine and on the Medical Faculty of University of Zurich, and Founding Director, Chair, Full Professor of Evolutionary Medicine.

Continue reading “The Health Past Of Mummies: Evolutionary Medicine Insights For Human Diseases Now” »

Circa 2017 Bats harbor a large diversity of coronaviruses (CoVs), several of which are related to zoonotic pathogens that cause severe disease in humans. Our screening of bat samples collected in Kenya from 2007 to 2010 not only detected RNA from several novel CoVs but, more significantly, identified sequences that were closely related to human CoVs NL63 and 229E, suggesting that these two human viruses originate from bats. We also demonstrated that human CoV NL63 is a recombinant between NL63-like viruses circulating in Triaenops bats and 229E-like viruses circulating in Hipposideros bats, with the breakpoint located near 5′ and 3′ ends of the spike (S) protein gene. In addition, two further interspecies recombination events involving the S gene were identified, suggesting that this region may represent a recombination “hot spot” in CoV genomes. Finally, using a combination of phylogenetic and distance-based approaches, we showed that the genetic diversity of bat CoVs is primarily structured by host species and subsequently by geographic distances.

^bMarie Bashir Institute for Infectious Diseases and Biosecurity, Charles Perkins Centre, School of Life and Environmental Sciences and Sydney Medical School, The University of Sydney, Sydney, Australia.

Find articles by Mang Shi

Continue reading “Surveillance of Bat Coronaviruses in Kenya Identifies Relatives of Human Coronaviruses NL63 and 229E and Their Recombination History” »